RxDoctor Payments Data

Himanshu Pandya, MD

Internal Medicine · Floral Park, NYNPI 1003896929

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 100 payments — averaging $40.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$1K
  • AstraZeneca$727
  • Boehringer Ingelheim$407
  • Boston Scientific$369
  • Johnson & Johnson$270
  • GSK$253
  • plus $1K from 9 others

What the payments were for

  • Travel & lodging$1,02625%
  • Food & beverage$3,04975%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,080 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$303,285
Medicare patients
626
Services billed
3,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban597$253,158
JanuviaSitagliptin Phosphate305$181,267
JardianceEmpagliflozin215$173,041
OzempicSemaglutide109$113,657
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate29$97,893
FarxigaDapagliflozin Propanediol100$91,865
JanumetSitagliptin Phos/Metformin Hcl79$78,196
Diclofenac Sodium304$58,687
TradjentaLinagliptin38$34,921
RytaryCarbidopa/Levodopa29$34,345
TivicayDolutegravir Sodium14$29,579
LinzessLinaclotide29$29,029
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog75$24,900
EntrestoSacubitril/Valsartan43$23,863
TrulicityDulaglutide20$20,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$16$259,263608 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$407$221,798271 claims
AstraZenecaFarxiga, Symbicort, Lokelma$727$116,087169 claims
Lilly USA, LLCTrulicity$160$20,26520 claims
Johnson & JohnsonXarelto$270$11,46520 claims
GSKIncruse Ellipta$253$10,39621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Floral Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →